[1]
|
Fellinger, K. and Schmid, J. (1952) Local Therapy of Rheumatic Diseases. Wiener Zeitschrift fur innere Medizin, 33, 351-363.
|
[2]
|
Schneider, P., Farahati, J. and Reiners, C. (2005) Radiosynovectomy in Rheumatology, Orthopedics, and Hemophilia. Journal of Nuclear Medicine, 46, 48-54.
|
[3]
|
Szerb, I., Gál, T., Mikó, I. and Hangody, L. (2021) Radiosynoviorthesis in the Treatment of Posttraumatic Joint Bleedings of Hemophilic Patients (Concerning Hip, Knee and Ankle Joints)-Hungarian Experience. Injury, 52, 53-56. https://doi.org/10.1016/j.injury.2020.02.054
|
[4]
|
Bagheri, R., Afarideh, H., Maragheh, M.G., Shirmardi, S.P. and Samanı, A.B. (2015) Study of Bone Surface Absorbed Dose in Treatment of Bone Metastases via Selected Radiopharmaceuticals: Using MCNP4C Code and Available Experimental Data. Cancer Biotherapy and Radiopharmaceuticals, 30, 174. https://doi.org/10.1089/cbr.2014.1730
|
[5]
|
Knut, L. (2015) Radiosynovectomy in the Therapeutic Management of Arthritis. World Journal of Nuclear Medicine, 14, 10. https://doi.org/10.4103/1450-1147.150509
|
[6]
|
Koc, B., Kılıcoglu, O. and Turkmen, C. (2020) Prognostic Factors of Radiosynovectomy in Haemophilia Patients with Inhibitors: Survival Analysis in a 19-Year Period. Haemophilia, 26, 855-860. https://doi.org/10.1111/hae.14091
|
[7]
|
Lee, E.B., Shin, K.C., Lee, Y.J., Cheon, G.J. Jeong, J.M., Son, M.W. and Song, Y.W. (2003) 188Re-Tin-Colloid as a New Therapeutic Agent for Rheumatoid Arthritis. Nuclear Medicine Communications, 24, 689-696. https://doi.org/10.1097/00006231-200306000-00012
|
[8]
|
Farahati, J., Kazek, S., Maric, I., Soestwoehner, T., Kalle, P., Costa, P.F., Jentzen, W., Stein, L., Jalilian, A., Kumm, D., Bockisch, A. and Herrmann, K. (2019) Post-Radi- osynovectomy Imaging Utilizing Erbium-169 Citrate. Applied Radiation and Isotopes, 154, Article ID: 108853. https://doi.org/10.1016/j.apradiso.2019.108853
|
[9]
|
Kampen, W.U., Brenner, W., Czech, N. and Henze, E. (2002) Intraarticular Application of Unsealed Beta-Emitting Radionuclides in the Treatment Course of Inflammatory Joint Diseases. Current Medicinal Chemistry, 1, 77-87. https://doi.org/10.2174/1568014024606502
|
[10]
|
Jha, P., Arora, G., Shamim, S.A., Mukherjee, A., Gautam, D., Ballal, S., Kumar, U., Ansari, T.M. and Bal, C. (2018) Lutetium-177 Tin Colloid Radiosynovectomy in Patients with Inflammatory Knee Joint Conditions Intractable to Prevailing Therapy. Nuclear Medicine Communications, 39, 803-808. https://doi.org/10.1097/MNM.0000000000000871
|
[11]
|
Brechbiel, M.W. (2007) Targeted Alpha-Therapy: Past, Present, Future? Dalton Transactions, 43, 4918-4928. https://doi.org/10.1039/b704726f
|
[12]
|
Elgqvist, J., Frost, S., Pouget, J.P. and Albertsson, P. (2014) The Potential and Hurdles of Targeted Alpha Therapy—Clinical Trials and Beyond. Frontiers in Oncology, 3, Article No. 324. https://doi.org/10.3389/fonc.2013.00324
|
[13]
|
Robertson, A.K.H., Ramogida, C.F., Schaffer, P. and Radchenko, V. (2018) Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences. Current Radiopharmaceuticals, 11, 156-172. https://doi.org/10.2174/1874471011666180416161908
|
[14]
|
Wilbur, S.D. (2011) Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides. Current Radiopharmaceuticals, 4, 214-217. https://doi.org/10.2174/1874471011104030214
|
[15]
|
Nilsson, S., Larsen, R.H., Fosså, S.D., Balteskard, L., Borch, K.W., Westlin, J.E., Salberg, G. and Bruland, O.S. (2005) First Clinical Experience with Alpha-Emitting Radium-223 in the Treatment of Skeletal Metastases. Clinical Cancer Research, 11, 4451-4459. https://doi.org/10.1158/1078-0432.CCR-04-2244
|
[16]
|
Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N.J., Coleman, R.E., O’Sullivan, J.M., Reuning-Scherer, J., Shan, M., Zhan, L. and Parker, C. (2016) Patient-Reported Quality-of-Life Analysis of Radium-223 Dichloride from the Phase III ALSYMPCA Study. Annals of Oncology, 27, 868-874. https://doi.org/10.1093/annonc/mdw065
|
[17]
|
Hallqvist, A., Bergmark, K., Bäck, T. andersson, H., Dahm-Kähler, P., Johansson, M., Lindegren, Jensen, S.H., Jacobsson, L., Hultborn, R., Palm, S. and Albertsson, P. (2019) Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. Journal of Nuclear Medicine, 60, 1073-1079. https://doi.org/10.2967/jnumed.118.220384
|
[18]
|
Delpassand, E., Tworowska, I., Shanoon, F., Nunez, R., Flores, L., Muzammil, A., Stallons, T., Saidi, A. and Torgue, J. (2019) First Clinical Experience Using Targeted Alpha-Emitter Therapy with Pb-212-DOTAMTATE (AlphaMedix TM) in Patients with SSTR(+) Neuroendocrine Tumors. Journal of Nuclear Medicine, 60, 559.
|
[19]
|
Kratochwil, C., Giesel, F.L., Bruchertseifer, F., Mier, W., Aposdolidis, C., Boll, R., Murphy, K., Haberkorn, U. and Morgestren, A. (2014) 213Bi-DOTATOC Receptor- Targeted Alpha-Radionuclide Therapy Induces Remission in Neuroendocrine Tumours Refractory to Beta Radiation: A First-in-Human Experience. European Journal of Nuclear Medicine and Molecular Imaging, 41, 2106-2119. https://doi.org/10.1007/s00259-014-2857-9
|
[20]
|
Kratchowil, C., Bruchertseifer, F., Giesel, F.L., Weis, M., Verburg, F.A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U. and Morgenstern, A. (2016) 225Ac- PSMA-617 for PSMA-Targeted-Radiation Therapy of Metastatic Castration-Resis- tant Prostate Cancer. Journal of Nuclear Medicine, 57, 1941-1944. https://doi.org/10.2967/jnumed.116.178673
|
[21]
|
Eryilmaz, K. and Kilbas, B. (2022) Detailed Chemistry Studies of 225Actinium Labeled Radiopharmaceuticals. Current Radiopharmaceuticals. https://doi.org/10.2174/1874471014666210528123936
|
[22]
|
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L. and Bruchertseifer, F. (2018) An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth. Current Radiopharmaceuticals, 11, 200-208. https://doi.org/10.2174/1874471011666180502104524
|
[23]
|
Trujillo-Nolasco, M., Morales-Avila, E., Cruz-Nova, P., Katti, K.V. and Ocampo- García, B. (2021) Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications. Pharmaceutics, 13, 1123. https://doi.org/10.3390/pharmaceutics13081123
|
[24]
|
Enrique, M.-A., Mariana, O.-R., Mirshojaei, S.F. and Ahmadi, A. (2015) Multifunctional Radiolabeled Nanoparticles: Strategies and Novel Classification of Radiopharmaceuticals for Cancer Treatment. Journal of Drug Targeting, 23, 191-201. https://doi.org/10.3109/1061186X.2014.988216
|
[25]
|
Viana, R.D.S., Costa, L.A.DM., Harmon, A.C., Gomes Filho, M.A., Falcão, E.H.L., Vicente, M.G.H., Junior, S.A. and Mathis, J.M. (2020) 177Lu-Labeled Eu-Doped Mesoporous SiO2 Nanoparticles as a Theranostic Radiopharmaceutical for Colorectal Cancer. ACS Applied Nano Materials, 3, 8691-8701. https://doi.org/10.1021/acsanm.0c01427
|
[26]
|
Cędrowska, E., Pruszynski, M., Majkowska-Pilip, A., Męczyńska-Wielgosz, S., Bruchertseifer, F., Morgenstern, A. and Bilewicz, A. (2018) Functionalized TiO2 Nanoparticles Labelled with 225Ac for Targeted Alpha Radionuclide Therapy. Journal of Nanoparticle Research, 20, 83. https://doi.org/10.1007/s11051-018-4181-y
|
[27]
|
Woodward, J., Kennel, S.J., Stuckey, A., Osborne, D., Wall, J., Rondinone, A.J., Standaert, R.F. and Mirzadeh, S. (2011) LaPO4 Nanoparticles Doped with Actinium225 that Partially Sequester Daughter Radionuclides. Bioconjugate Chemistry, 22, 766-776. https://doi.org/10.1021/bc100574f
|
[28]
|
Kruijff, R.M., Raavé, R., Kip, A., Molkenboer-Kuenen, J., Morgenstern, A., Bruchertseifer, F., Heskamp, S. and Denkova, A.G. (2019) The in Vivo Fate of 225Ac Daughter Nuclides Using Polymersomes as a Model Carrier. Scientific Reports, 9, Article No. 11671. https://doi.org/10.1038/s41598-019-48298-8
|
[29]
|
McLaughlin, M.F., Woodward, J., Boll, R.A., Wall, J.S., Rondinone, A.J., Kennel, S.J., Mirzadeh, S. and Robertson, J.D. (2013) Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy. PLoS ONE, 8, e54531. https://doi.org/10.1371/journal.pone.0054531
|
[30]
|
Kratochwil, C., Haberkorn, U. and Giesel, F.L. (2019) Radionuclide Therapy of Metastatic Prostate Cancer. Seminars in Nuclear Medicine, 49, 313-325. https://doi.org/10.1053/j.semnuclmed.2019.02.003
|
[31]
|
Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Lindén, O., Noordzij, W., Park, J. and Saad, F. (2018) Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncology, 4, 1765-1772. https://doi.org/10.1001/jamaoncol.2018.4044
|
[32]
|
Arora, G., Singh, M., Jha, P., Tripathy, S., Bal, C., Mukherjee, A. and Shamim, S.A. (2017) Formulation and Characterization of Lutetium-177-Labeled Stannous (Tin) Colloid for Radiosynovectomy. Nuclear Medicine Communications, 38, 587-592. https://doi.org/10.1097/MNM.0000000000000684
|